Background. Increased circulating visfatin may be associated both with endothelial damage and with increased mortality in end-stage renal disease (ESRD). HDL cholesterol is an independent, strong inverse predictor of cardiovascular events. However, associations between visfatin and parameters of lipid metabolism are unclear. Moreover, serum concentrations of visfatin measured by an enzyme immuno assay (EIA) are conflicting and do not correlate with ELISA (enzyme-linked immunosorbent assay) data, which predominantly detect enzymatically active visfatin. Methods. A total of 74 haemodialysis (HD) patients and 35 control individuals (C) were studied. All subjects (mean age 62.9 years) provided fasted blood samples (HD patients after 66-69 h without dialysis). Circulating visfatin was measured by the ELISA. Body composition was evaluated using waist circumference, skinfold thickness and body impedance analysis. Results obtained by the ELISA were compared with EIA data. Results. Active serum visfatin was increased in HD (5.58 ± 6.50 ng/ml) versus C [0.97 ± 1.79 ng/ml, mean ± SD; P < 0.0001 by multiple regression analysis (MRA)] independently of plasma glucose, serum insulin, diabetes, HDL cholesterol and body composition. Within the HD group, only plasma HDL cholesterol (4% lower per additional mg/dl HDL; P = 0.001) and insulin-treated diabetes mellitus [subgroup of n = 18; 119% higher compared with patients without diabetes (n = 40); P = 0.011] were independently (by MRA) associated with active serum visfatin. Visfatin measured by an EIA showed no correlation with ELISA data. Conclusions. Our study provides reliable data on active visfatin in HD patients using a well-characterized ELISA. Loss of renal function is accompanied by increased circulating active visfatin concentrations in our patients. Furthermore, decreased HDL cholesterol may hint at an increased probability of cardiovascular events in HD patients with elevated serum visfatin.
Introduction
Extracellular visfatin (eNAMPT/PBEF) is a cytokine predominantly secreted by adipocytes [1, 2] . In the last 2 years, conflicting results on circulating visfatin concentrations in humans have been reported. So far, visfatin has been quantified almost exclusively by a C-terminal enzyme immuno assay (EIA) [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . However, the EIA yields imprecise results [14] and specifically detects an undefined protein with a molecular weight (MW) of ∼500 kilodalton (kDa) [15] . Recovery of full-length human visfatin (MW 52 kDa) is insufficient [15, 16] . Therefore, quantification of circulating visfatin by a well-characterized, specific enzyme-linked immunosorbent assay (ELISA) is recommended. The ELISA predominantly detects dimeric visfatin, which is the enzymatically active form [2, 15] .
In patients with end-stage renal disease (ESRD), elevated serum visfatin concentrations have been reported using the EIA [11] [12] [13] . No association with visfatin has been shown for adiposity, nor for parameters of glucose metabolism in ESRD patients [11] . In contrast, measurements of our group by the EIA indicated decreased circulating visfatin and a positive association with body fat mass in maintenance haemodialysis (HD) patients [17] . This resembles the contradictory results in obese as well as diabetic patient groups [3] [4] [5] [6] [7] [8] [9] [10] . Recently, Ziegelmeier et al. [18] , who used the ELISA, described elevated serum visfatin in both diabetic and non-diabetic patients on maintenance HD.
Several studies have shown that circulating visfatin is identical to extracellular nicotinamide 5-phosphoribosyl-1-pyrophosphate transferase (eNAMPT), an enzyme that catalyzes the rate-limiting step in nicotinamide adenine dinucleotide (NAD) biosynthesis [2, 19] . Therefore, visfatin has a critical impact on energy availability, function and survival of cells [20] . Particularly, visfatin activity determines the energy status of the pancreatic β-cell. Reduced visfatin activity leads to lower NAD availability, resulting in decreased glucose-mediated insulin secretion [2] . Moreover, there is increasing evidence that hypervisfatinaemia is associated with impaired endothelial function and higher mortality in patients with ESRD [11, 12] . HDL cholesterol is an independent, strong inverse predictor of cardiovascular events [21, 22] . However, clear associations between visfatin and parameters of lipid metabolism have not been established. In this study, enzymatically active visfatin in the serum of healthy controls (C) and maintenance (HD) patients was measured using the well-characterized ELISA. We focused on a putative association of active serum visfatin with body composition as well as parameters of glucose and lipid metabolism in HD patients. Finally, data obtained by the ELISA were compared with those measured by the EIA.
Subjects and methods

Subjects
The study was approved by the ethics committee of the University of Erlangen-Nürnberg. All persons included gave informed written consent to participate.
A total of 109 individuals were included in this cross-sectional study: 74 patients with ESRD treated by maintenance HD from three different outpatient dialysis clinics (group HD, Table 1 ), and 35 control subjects (group C, Table 1 ) with similar age, sex and body mass index (BMI). All participants had to be aged ≥18 years and in a fasted state to be included in the study.
Controls were healthy volunteers. Criteria for exclusion were clinical signs or laboratory findings of renal disease, inflammatory disease, malignancies, metabolic disease or diabetes mellitus and need for any medication.
For subjects of the HD group, exclusion criteria were clinical signs or laboratory findings of generalized inflammatory disease, end stage malignancies or diabetes mellitus other than type 2, growth hormone therapy, known mutation of the insulin receptor and excessive hyperhydration >7 l. A total of 81 HD patients were screened, 7 of them were excluded (no informed consent, n = 3; diabetes mellitus type 1, n = 1; not fasted, n = 2; excessive hyperhydration, n = 1). ESRD was caused by diabetic nephropathy (25 patients), glomerulonephritis (21) , hypertensive nephropathy (13), polycystic kidney disease (6), reflux nephropathy (1) or was of unknown origin (8) . Three patients had a history of allograft failure. Concomitant diseases were arterial hypertension (56 patients), diabetes mellitus type 2 (34), hyperlipoproteinaemia (28) , hyperuricaemia (20) , coronary heart disease (27) , cardiac insufficiency (20) , pulmonary obstruction (14) and 11 other diagnoses (1-8 patients each). A total of 24 patients were anuric (urine volume 0-50 ml/day), 12 patients oliguric (urine volume between 100 ml/day and <500 ml/day) and 31 patients had urine volumes of 500-2500 ml/day. Residual diuresis was not recordable in seven patients.
A total of 59 patients received antihypertensive drugs, e.g. beta-blockers (42 patients), diuretics (27) , calcium channel blockers (20) , ACE inhibitors (19) , ATII-receptor antagonists (10), alpha-blockers (7) and imidazoline receptor agonists (6) . Further medications were phosphate binders (63 patients), alpha-calcidiol (27) , cinacalcet (13) , calcitriol (5), recombinant human erythropoietin or darbepoetin (50), intravenous iron(III)-sodiumgluconate (43), allopurinol (22) , statins (32) , acetyl salicylic acid (41), clopidogrel (9) , nitrates (15) , digitoxin (14) , proton pump inhibitors (36) , levothyroxine (12) , oral bicarbonate (9), metamizol (14) , antihistamines (8) and other drugs (1-6 patients each). Eighteen patients were treated with insulin. Ten of them injected insulin subcutaneously 15-45 min before blood sampling: insulin lispro (1 patient), insulin aspart (2), short-acting insulin (3), short-and long-acting insulin (3), long-acting insulin (1). In the remaining eight patients, the last insulin injection was >10 h ago: short-acting insulin (4), short-and long-acting insulin (3), long-acting insulin (1) .
Glomerular filtration rate (GFR) was calculated by the MDRD formula (four parameters). In HD patients, the mean calculated GFR after 66-69 h without dialysis was 5.90 ± 2.57 ml/min/1.73 m 2 .
Haemodialysis regimen
Patients were dialyzed three times per week for 3-6 h. The ultrafiltration rate (UF) was between 620 ml and 6000 ml per session. The following filters were used: Fresenius R Kap LO-PS-18 (18 patients), Kap FDX-150-GW (13), Kap PES-150-DH (14) , Kap PES-150-DL (8), Kap Polyflux-14-L (6) and 6 other filters (1-3 patients each).
Sample collection EDTA-plasma, lithium-heparinate plasma and serum samples were collected in fasted subjects (in HD patients before dialysis at the end of an interval of 66-69 h without dialysis) between 6:45 and 9:45 a.m. and processed within 5-60 min. Routine laboratory measurements were performed instantly. Aliquots for visfatin (serum) and insulin measurements (serum) were stored immediately at -25 • C.
Laboratory measurements
Enzymatically active, dimeric visfatin concentration in serum was determined with an ELISA kit (Adipogen, Germany). All samples were measured in duplicates. The detection range was 0.03-16 ng/ml with an interassay variance of 6.31-9.53% and an intraassay variance of 3.46-5.53% according to the manufacturer. Only for comparison with data obtained by the ELISA, additional measurements of EDTA-plasma were performed using a visfatin-EIA kit (Phoenix Pharmaceuticals, USA) [14] . All samples were again measured in duplicates. The detection range was 0.1-1000 ng/ml, the interassay variation <14% and the intraassay variation <5% for the visfatin peptide standard, according to the manufacturer. Insulin concentration in serum was determined with a DSL-1600 RIA kit (DSL, TX, USA). Other laboratory parameters were measured by routine methods.
Auxological data
Height and waist circumference above the pelvic bone were obtained to the nearest 0.1 cm, and body weight (BW) was obtained to the nearest 0.1 kg after dialysis (because hyperhydration prior to dialysis causes incorrect data). BMI was calculated as BW in kilograms divided by the square of height in metres. Subscapular (S), biceps (B) and triceps (T) skinfold thickness were measured during dialysis to the nearest 0.1 cm with a calliper by the same investigator. The mean skinfold thickness was calculated using the equation (S+B+T)/3. Body composition was additionally evaluated by body impedance analysis (BIA101, MediCal HealthCare, Germany) at the end of dialysis as recommended, because hyperhydration prior to dialysis causes incorrect BIA data. The parameters determined were total body water relative to BW (TBW%), extracellular water relative to total body water (ECW%) as well as body cell mass (BCM%) and fat mass (FM%) relative to BW. Calculation of body composition by BIA closely correlates with data obtained by CT in healthy subjects [23] and with dual-energy x-ray absorptiometry, deuterium oxide and sodium bromide isotope dilution studies in HD patients [24, 25] . The homeostasis model assessment of insulin resistance (HOMA IR ) was calculated as HOMA IR = insulin (µU/ml) × glucose (mmol/l)/22.5.
Statistical analysis
All data are shown as mean ± SD. Bivariate analyses were performed using Mann-Whitney U-tests, χ 2 tests or Spearman correlation where appropriate. A P-value (two-tailed) of <0.05 was considered significant, without adjusting for multiple comparisons.
In all individuals (n = 109), a multiple linear regression analysis (MRA1) was performed to analyse whether there is an independent association of fasted active serum visfatin with the following variables: age, mean skinfold thickness, plasma glucose, serum insulin, plasma HDL cholesterol, diabetes (no diabetes, diabetes without insulin therapy, diabetes with insulin therapy) and groups (C, HD). In preparation for this, visfatin measurements of zero were replaced by the lower limit of detection (0.1 ng/ml), and visfatin was log-transformed to approximate normality. Models including all variables and, because of inter-correlation of some parameters, models using standard backward variable selection (exit probability 0.1) were performed.
In a similar way, multiple linear regression analysis (MRA2) was performed for HD patients only (n = 74) investigating the same variables as in MRA1 but without the 'group' variable. The variable diabetes (no diabetes, diabetes without insulin therapy, diabetes with insulin therapy) adjusts MRA2 for diabetes and the modality of diabetes treatment. Thus, this variable provides information whether diabetic HD patients without insulin therapy (n = 16) show a difference in visfatin concentrations compared to non-diabetic HD patients (n = 40). The same information is provided for diabetic HD patients with insulin therapy (n = 18). Because one HD patient (with diabetes, without insulin therapy) showed an insulin outlier (158.96 µU/ml), analyses were performed both including and excluding this patient to obtain reliable results.
Furthermore, Spearman correlation analysis was performed to compare the measurement results of the ELISA and the EIA.
Results
Bivariate analyses of body composition and laboratory parameters
Because of matching, controls and HD patients showed similar BMI. Total body water was also similar in both groups. However, HD patients revealed increased relative extracellular water content and a concomitantly decreased relative body cell mass (functional tissues, e.g. organs, muscles). Relative fat mass was slightly increased in the HD group, and HD patients showed an altered fat distribution with a clearly reduced mean skinfold thickness (subcutaneous fat mass) but increased waist circumference (visceral fat mass; P < 0.001). All data are summarized in Table 1 .
Most interestingly, enzymatically active visfatin was increased in the sera of HD patients (Figure 1) . Compared with the controls, the HD group showed similar plasma HbA1c and fasted plasma glucose, but increased insulin concentrations and HOMA IR . C-reactive protein (CRP), a marker of inflammation, was also increased in the HD group. Furthermore, HD patients showed increased triglycerides but decreased total cholesterol, LDL cholesterol and HDL cholesterol (Table 1) .
Multiple regression analysis of active serum visfatin in all individuals
MRA1 in all individuals (n = 109) confirmed an independent association between group membership (C, HD) and active serum visfatin concentrations with elevated concentrations in the HD group (P < 0.0001). Additionally and most interestingly, MRA1 showed an independent inverse association of HDL cholesterol with visfatin (P = 0.019) in all individuals. Differences in all other parameters (age, mean skinfold thickness, plasma glucose, serum insulin, diabetes) were not significant. Exclusion of the patient with the insulin outlier did not modify the results. An additional multiple regression analysis (MRA) of all individuals without diabetes (n = 75; 35 controls and 40 HD patients) showed similar results (group, P < 0.0001; HDL cholesterol, P = 0.031).
Correlation analyses and MRA of active serum visfatin in HD patients
The results of bivariate correlation analyses between active serum visfatin and other parameters in HD patients only (n = 74) are summarized in Table 2 . A significant negative correlation was seen between HDL cholesterol and active serum visfatin (see also Figure 2 ). Furthermore, both serum insulin and mean skinfold thickness were positively associated with active serum visfatin. However, no significant correlation was found for other parameters of body composition, including body water, nor for GFR, residual diuresis or CRP (Table 2 ). There was also no association between sex and visfatin concentration (tested by the Mann-Whitney U-test; P > 0.10). However, these results have to be interpreted with caution because the HD group included patients with a typical, wide-ranging variety of renal and concomitant diseases, and particularly the presence of hyperglycaemia and hyperinsulinaemia, which were only found in patients with additional diabetes mellitus type 2, may lead to elevated active visfatin serum concentrations [16] . Therefore, we additionally performed a multiple linear regression analysis adjusted for diabetes and insulin therapy (MRA2) including the factors that were significant in the bivariate correlation analysis or predefined as of special interest (see the Subjects and methods section).
Most interestingly, MRA2 showed an independent, negative association between plasma HDL cholesterol and active serum visfatin concentrations in the HD group (4% lower per additional mg/dl HDL; P = 0.001). The same association was found when restricting the analysis to HD patients without diabetes (P = 0.006). Furthermore, compared to the non-diabetic cohort, patients with insulin-treated diabetes had a higher active serum visfatin concentration (119% increase; P = 0.011), whereas patients with diabetes but without insulin treatment had a similar serum visfatin concentration (P = 0.9) (overall P = 0.027). A weak positive association between serum insulin and visfatin disappeared after exclusion of the patient with the insulin outlier (P = 0.5). Visfatin was not significantly associated with age, mean skinfold thickness or plasma glucose.
Correlation analysis of ELISA and EIA data
Enzymatically active, dimeric visfatin concentrations detected by the ELISA did not show any correlation with the undefined, ∼500 kDa protein detected by the EIA, neither in controls (r = 0.13; P = 0.5) nor in HD patients (r = −0.06; P = 0.6; Figure 3 ).
Discussion
The most interesting result of our study is an inverse correlation between visfatin and circulating HDL cholesterol, which has not been previously reported. This correlation was shown to be independent of potential confounding factors such as glucose, insulin, diabetes or body composition. Furthermore, our visfatin measurements by a wellcharacterized ELISA [15] provide reliable information on serum visfatin in HD patients. The conflicting data reported so far were measured by the EIA [11] [12] [13] [14] 17] , which may not detect human visfatin sufficiently. A comparison of both assays in our study showed a complete absence of a correlation between visfatin ELISA and EIA data in HD patients, which so far has only been described in subjects with normal renal function [15, 16] . Moreover, we demonstrate that loss of renal function results in increased active serum visfatin concentrations in patients with ESRD treated by HD, similar to other studies using the EIA [11] or the ELISA [18] . The results resemble data on other adipokines such as leptin and resistin or IL-6, which also show elevated serum or plasma concentrations in advanced chronic renal failure [18, [26] [27] [28] .
In patients with chronic renal failure, elevated visfatin levels predict increased mortality [11] , most often caused by cardiovascular events [29] . Patients with artherosclerosis show increased visfatin concentrations [30] . An association between hypervisfatinaemia and endothelial dysfunction has been described in chronic renal failure [11, 12] . A positive correlation between visfatin and the proinflammatory cytokine resistin has also been reported for ESRD [18] . Moreover, resistin is increased particularly in dialysis patients with cardiovascular disease [31] . Our study shows a reduction of plasma HDL cholesterol at concomitantly increased serum visfatin concentrations. HDL cholesterol is an independent, strong inverse predictor of cardiovascular events [21, 22] . Therefore, the inverse correlation between visfatin and HDL cholesterol may provide an explanation for the increased rate of cardiovascular events in HD patients with high visfatin levels. Nevertheless, visfatin itself may protect cells. Circulating visfatin is identical to extracellular eNAMPT, an enzyme catalyzing the rate-limiting step in NAD biosynthesis [19] . Thus, visfatin activity has a critical impact on energy availability, function and survival of cells [20] . Increased visfatin gene expression and protein secretion promote both cell function and survival under conditions of hypoxia, poor nutrient supply or enhanced energy demand, for example because of inflammation [19, 32] . Direct cardioprotective effects of visfatin in mice have been previously described [33] . Therefore, adverse effects associated with elevated visfatin may be caused mainly by secondary factors, for example increased resistin or decreased HDL cholesterol. It is unlikely that the protective characteristics of visfatin are sufficient to balance these factors.
Inflammation and energy wasting, however, both major causes of mortality in HD patients [29] , may be promoted directly by visfatin. Visfatin itself is identical to pre-B cell colony-enhancing factor (PBEF) and has proinflammatory properties [34] . In our patients, increased plasma CRP concentrations provide evidence for inflammation, possibly accompanied by energy consumption. Visceral adiposity, also present in our patients, may further increase serum visfatin concentrations and promote inflammation, as human adipocytes have been shown to secrete visfatin using a non-classical secretory pathway [2] . Despite similar BMI compared to the control group, our HD patients show a serious disorder of body composition as demonstrated by decreased lean body mass at concomitantly increased extracellular water content, thus representing a high-risk group [35] . However, in our study active visfatin did not correlate significantly with parameters of fat mass or body composition in the multiple regression analyses. This resembles data from lean as well as subcutaneously or viscerally obese subjects without renal failure [15] . Moreover, CRP did not show any correlation with circulating visfatin. A limiting factor for the analysis was the small range of CRP concentrations, partially caused by exclusion of subjects showing inflammatory disease. In summary, our study provides neither clear evidence for an association of visfatin with body composition nor with inflammation in HD patients.
The third focus of our study was glucose metabolism. Since binding of visfatin to the insulin receptor could not be reproduced [2] , visfatin does not seem to have insulinmimetic properties via this pathway as initially described [1] . In fact, decreased visfatin activity results in reduction of both NAD availability in the pancreatic β-cell and glucose-mediated insulin secretion in vitro and in vivo, respectively. Administration of nicotinamide mononucleotide (NMN), the product of the reaction catalyzed by visfatin, reverses these effects [2] . We showed increased visfatin levels in patients with insulin-treated diabetes mellitus. This may indicate a compensatory mechanism, possibly aiming at increasing endogenous insulin secretion that probably is impaired in this patient group. However, as this secondary result was obtained in a small subgroup only (18 HD patients with diabetes and insulin treatment), it has to be interpreted with care. Our patients are rather heterogeneous because only 10 of 18 subjects injected insulin briefly before blood sampling. Moreover, we could neither demonstrate an independent correlation between elevated active serum visfatin and plasma insulin nor with glucose concentrations or the presence of diabetes mellitus type 2 without insulin therapy in HD patients. Therefore, one might assume that HD patients do not show a normal regulation of insulin by visfatin, and accumulation of visfatin due to renal failure leads to this decompensation. Nevertheless, insulin-resistant subjects with type 2 diabetes but without renal failure show elevated circulating active visfatin concentrations as a putative compensatory mechanism at concomitantly elevated glucose and insulin levels [16] . Therefore, at least in subjects without renal failure, visfatin has a critical impact on insulin regulation.
Our study is limited to correlation analyses. Furthermore, the study group contains a relatively low number (n = 74) of rather heterogeneous HD patients, with abundant concomitant diseases and medications. Especially, treatment with drugs affecting either glucose or lipid metabolism, for example statins, may influence circulating visfatin levels. However, atorvastatin downregulates visfatin gene expression in adipocytes and may promote apoptosis of these cells [36] . Data on visfatin protein concentrations either with or without statin treatment are not available, but an elevation of serum visfatin by statins appears to be implausible. Furthermore, ACE inhibitors as well as angiotensin II receptor blockers may stimulate the release of visfatin Elevation of active visfatin in serum of maintenance HD patients 2837 [37] . However, the authors discussed methodological concerns about the visfatin EIA used and showed no effect of incubation with angiotensin II on visfatin release from cultured adipocytes, myocytes and endothelial cells. Finally, the heterogeneity of the HD group may not only be considered as a limit of the study, as it provides a representative cross section of patients in our region and possibly in Western European countries. Patients were selected with clearly defined in-and exclusion criteria.
In summary, our study provides reliable data on enzymatically active visfatin in HD patients using a wellcharacterized ELISA. We found that loss of renal function is accompanied by increased circulating active visfatin concentrations. Most interestingly, HD patients show an inverse association between HDL cholesterol and active serum visfatin. HDL cholesterol is a strong inverse predictor of cardiovascular events. Therefore, reduced circulating HDL cholesterol may hint at an increased probability of cardiovascular events in HD patients with elevated serum visfatin concentrations.
